MYELOPROLIFERATIVE NEOPLASM

This study is for people with certain blood cancers (like leukemia) that have a specific genetic change called an IDH1 mutation. It tests a combination of two or three drugs: ivosidenib (targets the mutation), venetoclax (blocks a protein that helps cancer cells survive), and som…

This study tests whether giving a chemotherapy drug (decitabine) along with a JAK inhibitor (ruxolitinib, fedratinib, or pacritinib) before a stem cell transplant helps people with advanced myeloproliferative neoplasms (MPNs) get to transplant and have better outcomes. About 25 a…

This early-phase study tests whether specially trained immune cells (CIML NK cells) given after a stem cell transplant can safely prevent leukemia or related blood cancers from coming back. About 15 adults with high-risk acute myeloid leukemia, myelodysplastic syndrome, or relate…

This study tests a combination of two drugs, CPX-351 and ivosidenib, in about 30 people with a specific genetic form of acute myeloid leukemia or a related high-risk bone marrow disorder. The goal is to see if the combo can shrink or control the cancer. Participants must have the…

This study tests a refined cord blood transplant method for people with hard-to-treat blood cancers like leukemia and lymphoma. Participants receive chemotherapy and radiation before the transplant to kill cancer cells and prepare the body, then donor stem cells are infused to re…

This early-phase trial tests a special type of immune cell (CIML NK cells) combined with a low dose of IL-2 in people whose blood cancer (AML, MDS, MPN, or JMML) has returned after a stem cell transplant. The main goal is to find the safest dose and see if it can put the cancer b…

This study tests whether removing a specific type of immune cell (naive T cells) from donated stem cells can prevent chronic graft-versus-host disease (GVHD) in children and young adults with blood cancers. GVHD occurs when donor cells attack the patient's body, causing long-term…

This study compares two strategies to lower the risk of graft-versus-host disease (GVHD) in people with acute leukemia or myelodysplastic syndrome (MDS) who are getting a donor stem cell transplant. Participants will receive either a treatment that removes certain immune cells fr…

This study tests whether combining two drugs, venetoclax and azacitidine, is safe and effective for people with advanced myeloproliferative neoplasms (MPN), a rare blood cancer. About 40 participants will receive the combination to see if it can bring the disease back to a less a…

This early-stage study tests whether drugs that remove extra metals from the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. Researchers want to find the safest dose and see if lowering metal levels in blood…

This study tests whether a drug called dexrazoxane can protect the heart from damage caused by chemotherapy in people with certain blood cancers, like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). About 100 participants will receive dexrazoxane alongs…

This study tests whether giving a CMV vaccine to stem cell donors can protect transplant recipients from CMV infection. Donors receive the vaccine before donating stem cells, and the immunity is passed to the patient. The trial involves 216 people with blood cancers and aims to r…

This early-phase trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV) and prevent active infection after transplant. About 46 people with various blood cancers or disorders will take part. The goal i…

This study tests N-acetylcysteine (N-AC), a supplement, in 27 adults with certain blood cancers (myeloproliferative neoplasms). The goal is to find the best dose that reduces symptoms like fatigue and pain while being safe. Participants continue their usual treatments during the …

This study collects health information and leftover tumor or blood samples from children and young adults with cancer. The goal is to learn more about these diseases and find better ways to treat and care for patients over time. Up to 75,000 people will take part, and no experime…

This study looks at how services from Blood Cancer United (formerly The Leukemia & Lymphoma Society) affect people with blood cancers like leukemia, lymphoma, and myeloma. Researchers will track 400 patients over time to see if the organization helps with access to care, quality …

This study is looking at a type of immune cell called monocytes in people with certain blood cancers (myeloproliferative neoplasms). Researchers want to see if these cells have unique features that could help diagnose the disease or predict its course. About 70 participants will …

This study looks at why people with a CALR gene mutation and a type of blood cancer called MPN have a lower risk of dangerous blood clots than those with a JAK2 mutation. Researchers will measure certain immune markers and inflammatory proteins in blood samples from 35 adults wit…

This study looks at whether measuring changes in a gene called CALR over time can help doctors predict when certain blood cancers (myeloproliferative neoplasms) are getting worse. Researchers will follow 260 adults diagnosed between 2006 and 2020, using stored blood samples and m…

This study is testing whether an artificial intelligence tool can help match cancer patients to clinical trials they might be eligible for. Researchers will enroll up to 50,000 people with various types of cancer and use the AI to suggest trials. The goal is to see if this approa…

This study looks at how the body processes venetoclax when the tablets are crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. About 30 participants who already take venetoclax this way will have their blood levels measured.…

This study is for people with myeloproliferative neoplasms (MPNs), a group of blood cancers that raise the risk of dangerous blood clots. Researchers want to see if a marker called calprotectin in the blood can help predict who will get a clot. 300 participants will be followed o…

This study looks at how the drug interferon attacks the root cause of certain blood cancers called myeloproliferative neoplasms. Researchers will take blood samples from 80 adults to study cancer stem cells and their genetic makeup. The goal is to understand why some patients res…

This study is for adults with certain blood cancers (polycythemia vera, essential thrombocythemia, or pre-myelofibrosis) who are about to start their first treatment. The goal is to find biological markers, like genetic mutations and immune signals, that can predict whether a pat…